Table 3.
Cox proportional hazards model for DFS
| HR | p-value | 95% CI | |
|---|---|---|---|
| Age at diagnosis | 0.97 | 0.247 | 0.92–1.02 |
| Stage | |||
| 1 | Reference | ||
| 2 | 0.37 | 0.361 | 0.045–3.08 |
| 3 | 0.62 | 0.664 | 0.072–5.35 |
| Receptor subtype | |||
| ER+/PR+/HER2– | Reference | ||
| ER+/PR-/HER2– | 6.1 | 0.020 | 1.33–27.47 |
| HER2+ | 0 | N/A | N/A |
| Triple negative | 0 | N/A | N/A |
| Grade | |||
| Low/intermediate | Reference | ||
| High | 10.3 | 0.039 | 1.13–94.28 |
| Final positive margins | 3.41 | 0.087 | 0.84–13.89 |
| Local therapy | |||
| Lumpectomy with radiation | Reference | ||
| Lumpectomy alone | 0.78 | 0.769 | 0.15–4.0 |
| Mastectomy | 1.8 | 0.371 | 0.49–6.62 |
| Mastectomy with radiation | 0 | N/A | N/A |
| Adjuvant chemotherapy | 0.8 | 0.725 | 0.22–2.83 |
DFS disease-free survival, HR hazard ratio, CI confidence interval, N/A not applicable